Event at-a-glance
Veridon Global is proud to present the EVIDENCE 360: RWE, Pricing & Reimbursement Summit Europe on 26th-27th May 2025 in Frankfurt, Germany. This two-day summit is a must-attend event for healthcare professionals, pharmaceutical leaders, policymakers, and researchers, offering an in-depth exploration of the latest trends, challenges, and innovations in Real-World Evidence (RWE), pricing strategies, and reimbursement frameworks in Europe.
As the healthcare landscape evolves, RWE is becoming increasingly vital for decision-making, influencing how drugs are priced, reimbursed, and integrated into healthcare systems. This summit will address the current challenges in RWE adoption, including the complexities of data quality, integration of electronic health records, addressing key topics such as the integration of RWE into pricing strategies, the alignment of RWE with health technology assessments (HTAs), and the complexities surrounding cross-border reimbursement policies. Attendees will gain valuable insights into the evolving role of RWE in shaping pricing models and market access strategies within the European context, focusing on how healthcare systems are evolving to incorporate this data for more value-based and patient-centric decisions.
With a series of expert-led sessions, panel discussions, and networking events, the EVIDENCE 360 summit will equip attendees with the knowledge and tools for overcoming data silos, ensuring better access to high-quality real-world data, and developing actionable solutions that can navigate the complex regulatory and reimbursement environments. Don’t miss the opportunity to be part of this high-impact event that will shape the future of healthcare decision-making.
Key Topics
- The rise of data analytics tools—how AI, machine learning, and big data are shaping the future of RWE analysis and usage.
- Managing regional disparities in reimbursement policies and the need for harmonization of pricing models across Europe.
- Navigating regulatory challenges surrounding RWE data acceptance, standardization, and quality control in European markets.
- Leveraging patient-centered data and incorporating Patient Reported Outcomes (PRO’s) to better address unmet needs and optimize healthcare access.
- Understanding how RWE influences HTAs in Europe, with a focus on improving the alignment between pricing, reimbursement decisions, and clinical effectiveness.
- The Future of Personalized Medicine and its Impact on Pricing and Reimbursement
Why join us?
- Gain insights into the latest RWE trends and how they influence pricing and reimbursement strategies in Europe.
- Network with key industry leaders and regulators shaping the future of healthcare policy and market access.
- Learn about the role of RWE in regulatory decision-making and how it influences health technology assessments (HTAs).
- Explore the integration of AI and digital health in driving more efficient and effective reimbursement decisions.
- Collaborate on overcoming the key challenges in integrating RWE and enhancing patient outcomes through data-driven decisions.
Target Audience
- Pharmaceutical and Biotech Companies: Executives, decision-makers, and researchers involved in drug development, market access, and pricing strategies.
- Regulators and Policy Makers – Representatives from healthcare authorities, regulatory bodies, and health technology assessment (HTA) agencies across Europe.
- Researchers– Experts using RWE to assess treatment outcomes, improve healthcare models, and support regulatory submissions.
- Advisors and Payers – Professionals providing guidance on pricing strategies, reimbursement, and RWE implementation.
- Investors – Individuals and firms interested in funding innovation in healthcare, particularly in RWE and value-based pricing models.
